openPR Logo
Press release

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Serum biomarkers are expected to lead the global market

02-27-2018 10:57 AM CET | Health & Medicine

Press release from: TMR - Research Report

/ PR Agency: TMR - Research Report
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market:

Some of the leading players operating in the global non-alcoholic steatohepatitis (NASH) biomarkers market are One Way Liver S.L., Siemens Healthineers, Genfit, and SNIBE Diagnostics, observes Transparency Market Research. The majority of the players in the market are focusing on conducting clinical trials to introduce improved biomarkers that deliver accurate results. Companies are also expected to expand their distribution channels through strategic collaborations in the coming years.

According to the research report, the global NASH biomarkers market is expected to reach a valuation of US$1.7 bn by the end of 2024 as compared to US$201.2 mn in 2016. Between the forecast period of 2016 and 2024, the global market is projected to expand at a CAGR of 31.7%.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18650

Europe to Lead Global Market with a CAGR of 30.80% 2016-2024

On the basis of type, the global market is segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. Out of these, the hepatic fibrosis biomarkers segment is expected to progress at a phenomenal CAGR of 32.7% between 2016 and 2024. The growth of this segment will be attributable to the high accuracy and efficacy provided by these biomarkers.

In terms of geography, the overall market is fragmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. The report predicts that North America is likely to hold a significant share in the overall market in the coming years due to the emergence of NASH health care sector. However, Europe is expected to dominate the global market as it is estimated to progress at a CAGR of 30.80% between 2016 and 2024.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18650

Preference for Non-invasive Procedures Contributes to Soaring NASH Biomarkers Market Revenue

The rising prevalence of non-alcoholic liver diseases has been the primary growth driver for the NASH biomarkers market. The growing number type 2 diabetics are estimated to boost the overall market as this pool is population is prone to NAFLAD along with other liver diseases. The market is also anticipated to be driven by the changing lifestyles that are characterized by smoking, poor eating habits, and lack of exercise. The smothering rise in air pollution is also expected to drive the global NASH biomarkers market in the coming years.

The growing demand for non-invasive diagnostic techniques to determine the complication and stage of the liver diseases have also augmented the demand for NASH biomarkers. Due to the ability of reproduce the results, these biomarkers have become the preferred choice for diagnosing and monitoring NASH. The market is also slated to find an adequate drive in treating the unmet medical needs of NASH as the liver-related diseases are on the rise. Demand for low-cost diagnostic techniques as compared to liver biopsy, which requires hospital stay and anesthesia are also likely to encourage the growth of the global market.

Read Report Overview: https://www.transparencymarketresearch.com/non-alcoholic-steatohepatitis-biomarkers-market.html

Lack of Accuracy of Individual Biomarkers Restrains Market Growth

The limitations pertaining to the accuracy and sensitivity in determining the results in the key challenge for the players operating in the global NASH biomarkers market. Thus, the questionable accuracy of individual biomarkers and their panels is anticipated to restrain the growth of the overall market. Furthermore, the global NASH biomarkers market is also challenged by the overlapping results for other metabolic disorders. Since these biomarkers deliver overlapping results for metabolic diseases such as glycogenic hepatopathy, diabetic hepatosclerosis, and Wilson diseases the reliability of the biomarkers remains under question.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Serum biomarkers are expected to lead the global market here

News-ID: 959167 • Views:

More Releases from TMR - Research Report

Global Tissue Extraction System Market: Trends and Opportunities 2017 - 2025
Global Tissue Extraction System Market: Trends and Opportunities 2017 - 2025
Global Tissue Extraction System Market: Overview The global tissue extraction system market is foretold to display an impressive growth rate in the coming years. This could be owing to the need for tissue extraction or biopsy for cancer analysis after the patient has been suspected of carrying the disease. The procedure is extremely vital for diagnosing the disease. Thus, increasing prevalence of carcinogenic agents, compromised immunity levels, and rising incidence of
Neurology Sterile Injectable Market: Growth Factors, Applications, Regional Analysis 2017 - 2025
Neurology Sterile Injectable Market: Growth Factors, Applications, Regional Anal …
Neurology sterile injectables are generally administered to individuals suffering from pain linked to the nerves. Neuropathic pain injections are used to provide relief to these individuals. Neurology sterile injectable block the pain signal from reaching the brain. Neurological sterile injection can be administered at sympathetic nervous system, trigger points, dorsal roots, and peripheral nerves. The most commonly use neurological injectable used for nerve block are steroid injection, opioids, and local
External Fixator Devices Market: Global Survey and Trend Research
External Fixator Devices Market: Global Survey and Trend Research
External fixator devices are used to stabilize and support long bone open fractures to help the patient carry body’s weight as well as movement. Schanz screws, connecting rods, and clamps are used in case of unipolar external fixators. Circulatory fixators include circular rings, wires, connecting rods, and struts. The external fixator devices provide rigid fixation along with fixed distraction of the fracture fragments. The major advantage of external fixator devices
Anorectal Preparations Market Trends, and Forecast 2017 - 2025
Anorectal Preparations Market Trends, and Forecast 2017 - 2025
Anorectal preparations are products that contain a combination of an anti-inflammatory agent, or a pain reliever, and a local anesthetic as a suppository, or an ointment. External or internal hemorrhoids are treated by the topical application of anorectal preparations. Hemorrhoids are masses or lumps of tissue in the anus that contain enlarged blood vessels. The formation of hemorrhoids is due to an increase in abdominal pressure. Frequent constipation, which is

All 5 Releases


More Releases for NASH

The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date. The NASH
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028 The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining
NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will